Andrew Lawrence Taylor net worth and biography

Andrew Taylor Biography and Net Worth

Chief Financial Officer of Orchestra BioMed

Mr. Taylor joined Orchestra BioMed as its Chief Financial Officer (CFO) June 2023. He brings over 20 years of CFO experience with emerging growth companies, the last 15 of which were in the medical device sector.

Prior to joining Orchestra BioMed, Mr. Taylor served as CFO of Motus GI Holdings, Inc. (NASDAQ: MOTS), where he helped lead the company’s 2018 IPO. Prior to Motus GI, Mr. Taylor spent 10 years as CFO and President of Avertix Medical, Inc. (f/k/a Angel Medical Systems, Inc.), where he is still a member of the Board of Directors. Prior to Avertix, he was a Practice Leader for AC Lordi Consulting (now part of BDO USA, LLP) and CFO and Corporate Director of Operations for Safe3w, Inc. (acquired by iPass). Mr. Taylor earned a high-honors MBA with a concentration in Accounting and Finance from Northeastern University and a B.A. in Political Science and Economics from McGill University.

What is Andrew Lawrence Taylor's net worth?: The estimated net worth of Andrew Lawrence Taylor is at least $1.97 million as of August 25th, 2025. Mr. Taylor owns 482,788 shares of Orchestra BioMed stock worth more than $1,969,775 as of June 22nd. This net worth estimate does not reflect any other investments that Mr. Taylor may own. Learn More about Andrew Lawrence Taylor's net worth.
How do I contact Andrew Lawrence Taylor?: The corporate mailing address for Mr. Taylor and other Orchestra BioMed executives is 40 10TH AVENUE FLOOR 7, NEW YORK NY, 10014. Orchestra BioMed can also be reached via phone at 646-597-6980 and via email at [email protected]. Learn More on Andrew Lawrence Taylor's contact information.
Has Andrew Lawrence Taylor been buying or selling shares of Orchestra BioMed?: Andrew Lawrence Taylor has not been actively trading shares of Orchestra BioMed within the last three months. Most recently, on Monday, August 25th, Andrew Lawrence Taylor bought 2,000 shares of Orchestra BioMed stock. The stock was acquired at an average cost of $2.55 per share, with a total value of $5,100.00. Following the completion of the transaction, the chief financial officer now directly owns 482,788 shares of the company's stock, valued at $1,231,109.40. Learn More on Andrew Lawrence Taylor's trading history.
Are insiders buying or selling shares of Orchestra BioMed?: In the last year, Orchestra BioMed insiders bought shares 13 times. They purchased a total of 92,396 shares worth more than $321,714.25. In the last year, insiders at the sold shares 2 times. They sold a total of 17,683 shares worth more than $66,233.15. The most recent insider tranaction occured on June, 1st when insider David P Hochman bought 5,000 shares worth more than $19,150.00. Insiders at Orchestra BioMed own 7.5% of the company. Learn More about insider trades at Orchestra BioMed.
Information on this page was last updated on 6/1/2026.

Andrew Lawrence Taylor Insider Trading History at Orchestra BioMed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/25/2025	Buy	2,000	$2.55	$5,100.00	482,788
12/19/2024	Buy	1,000	$4.83	$4,830.00	344,960

Andrew Lawrence Taylor Buying and Selling Activity at Orchestra BioMed

Orchestra BioMed Company Overview

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Today's Range

Now: $4.08

$3.89

$4.12

50 Day Range

MA: $4.06

$3.72

$4.58

2 Week Range

Now: $4.08

$2.20

$5.42

Volume

260,353 shs

Average Volume

217,046 shs

Market Capitalization

$244.31 million

P/E Ratio

N/A

Dividend Yield